Historical Valuation
Kezar Life Sciences Inc (KZR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.73. The fair price of Kezar Life Sciences Inc (KZR) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：6.20
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Kezar Life Sciences Inc (KZR) has a current Price-to-Book (P/B) ratio of 0.56. Compared to its 3-year average P/B ratio of 0.48 , the current P/B ratio is approximately 15.48% higher. Relative to its 5-year average P/B ratio of 1.36, the current P/B ratio is about -59.27% higher. Kezar Life Sciences Inc (KZR) has a Forward Free Cash Flow (FCF) yield of approximately -123.00%. Compared to its 3-year average FCF yield of -133.97%, the current FCF yield is approximately -8.19% lower. Relative to its 5-year average FCF yield of -83.97% , the current FCF yield is about 46.49% lower.
P/B
Median3y
0.48
Median5y
1.36
FCF Yield
Median3y
-133.97
Median5y
-83.97
Competitors Valuation Multiple
AI Analysis for KZR
The average P/S ratio for KZR competitors is 10.36, providing a benchmark for relative valuation. Kezar Life Sciences Inc Corp (KZR.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for KZR
1Y
3Y
5Y
Market capitalization of KZR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of KZR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is KZR currently overvalued or undervalued?
Kezar Life Sciences Inc (KZR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.73. The fair price of Kezar Life Sciences Inc (KZR) is between NaN to NaN according to relative valuation methord.
What is Kezar Life Sciences Inc (KZR) fair value?
KZR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kezar Life Sciences Inc (KZR) is between NaN to NaN according to relative valuation methord.
How does KZR's valuation metrics compare to the industry average?
The average P/S ratio for KZR's competitors is 10.36, providing a benchmark for relative valuation. Kezar Life Sciences Inc Corp (KZR) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Kezar Life Sciences Inc (KZR) as of Jan 10 2026?
As of Jan 10 2026, Kezar Life Sciences Inc (KZR) has a P/B ratio of 0.56. This indicates that the market values KZR at 0.56 times its book value.
What is the current FCF Yield for Kezar Life Sciences Inc (KZR) as of Jan 10 2026?
As of Jan 10 2026, Kezar Life Sciences Inc (KZR) has a FCF Yield of -123.00%. This means that for every dollar of Kezar Life Sciences Inc’s market capitalization, the company generates -123.00 cents in free cash flow.
What is the current Forward P/E ratio for Kezar Life Sciences Inc (KZR) as of Jan 10 2026?
As of Jan 10 2026, Kezar Life Sciences Inc (KZR) has a Forward P/E ratio of -1.24. This means the market is willing to pay $-1.24 for every dollar of Kezar Life Sciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Kezar Life Sciences Inc (KZR) as of Jan 10 2026?
As of Jan 10 2026, Kezar Life Sciences Inc (KZR) has a Forward P/S ratio of 0.00. This means the market is valuing KZR at $0.00 for every dollar of expected revenue over the next 12 months.